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IMPORTANCE The discontinuation of randomized clinical trials (RCTs) raises ethical concerns
and often wastes scarce research resources. The epidemiology of discontinued RCTs,
however, remains unclear.
OBJECTIVES To determine the prevalence, characteristics, and publication history of
discontinued RCTs and to investigate factors associated with RCT discontinuation due to poor
recruitment and with nonpublication.
DESIGN AND SETTING Retrospective cohort of RCTs based on archived protocols approved by
6 research ethics committees in Switzerland, Germany, and Canada between 2000 and
2003. We recorded trial characteristics and planned recruitment from included protocols.
Last follow-up of RCTs was April 27, 2013.
MAIN OUTCOMES ANDMEASURES Completion status, reported reasons for discontinuation,
and publication status of RCTs as determined by correspondence with the research ethics
committees, literature searches, and investigator surveys.
RESULTS After a median follow-up of 11.6 years (range, 8.8-12.6 years), 253 of 1017 included
RCTs were discontinued (24.9% [95% CI, 22.3%-27.6%]). Only 96 of 253 discontinuations
(37.9% [95% CI, 32.0%-44.3%]) were reported to ethics committees. Themost frequent
reason for discontinuation was poor recruitment (101/1017; 9.9% [95% CI, 8.2%-12.0%]). In
multivariable analysis, industry sponsorship vs investigator sponsorship (8.4% vs 26.5%;
odds ratio [OR], 0.25 [95% CI, 0.15-0.43]; P < .001) and a larger planned sample size in
increments of 100 (−0.7%; OR, 0.96 [95% CI, 0.92-1.00]; P = .04) were associated with
lower rates of discontinuation due to poor recruitment. Discontinued trials were more likely
to remain unpublished than completed trials (55.1% vs 33.6%; OR, 3.19 [95% CI, 2.29-4.43];
P < .001).
CONCLUSIONS AND RELEVANCE In this sample of trials based on RCT protocols from 6
research ethics committees, discontinuation was common, with poor recruitment being the
most frequently reported reason. Greater efforts are needed to ensure the reporting of trial
discontinuation to research ethics committees and the publication of results of discontinued
trials.
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C onductinghigh-quality randomizedclinical trials (RCTs)is challenging and resource-demanding. Trials are of-ten not conducted as planned or are even prematurely
discontinued, eg, for reasonsofunexpectedharm fromthe in-
tervention, early superiority, futility, administrative prob-
lems, or poor recruitment of participants. Trial discontinua-
tion poses ethical concerns, particularly if results remain
unreported, andmay represent a considerablewaste of scarce
research resources.1-3
Currently, little is knownabout theepidemiologyandpub-
lication history of discontinued trials. Although studies have
highlighted frequent recruitment problems inRCTs, fewhave
empirically addressed factors associated with failure (or suc-
cess) of patient recruitment, yielding uncertain results.4-6We
established an international retrospective cohort of RCT pro-
tocols to determine: (1) the prevalence of RCT discontinua-
tion and its reasons, (2) differences betweenRCTswith inves-
tigator sponsorshipor industrysponsorship, (3) thepublication
history of discontinued RCTs, (4) factors associatedwith trial
discontinuation due to poor recruitment, and (5) factors as-
sociated with nonpublication.
Methods
Study Design
Theprotocolof this studyhasbeenpublished.3Briefly,wecon-
ducted a retrospective cohort study using RCT protocols ap-
proved between 2000 and 2003 by 6 research ethics commit-
tees (RECs) in Switzerland (Basel, Lucerne, Zurich, and
Lausanne), Germany (Freiburg), and Canada (Hamilton, On-
tario). Of these RECs, all but 1 are responsible for human re-
search in large university centers and additional hospitals in
their respective catchment areas; the Lucerne REC covers an
academic teaching hospital. As a convenience sample we ap-
proached the RECs through existing contacts. The participat-
ing RECs approved this study or explicitly stated that no ethi-
cal approval was necessary.
Definitions
We considered an RCT discontinued if the investigators indi-
cateddiscontinuationwithareason in thecorrespondencewith
theREC, ina journalpublication,or in their response toour sur-
vey (seebelow). Ifwecouldnotelucidate thereasonfor trialdis-
continuation or if poor participant recruitment was men-
tioned,weusedaprespecifiedcutoffof lessthan90%ofachieved
target samplesize (and inasensitivityanalysisof less than80%)
to determine discontinuation.3 Reviewers assessedRCTproto-
cols for industry sponsorshipor investigator sponsorshipusing
the following criteria: The protocol clearly named the sponsor;
displayed a company or institution logo prominently; men-
tioned affiliations of protocol authors; or included statements
aboutdataownershiporpublication rightsor statementsabout
full funding by industry or public funding agencies.7 Disagree-
ments were resolved by consensus. We regarded peer-
reviewed journal publications other than conference abstracts
orresearchlettersasfullpublications.Furtherdetailsaboutthese
and other working definitions of study variables are provided
in eTable 1 in Supplement. We a priori defined RCTs involving
healthy volunteers as a subgroup, because we anticipated that
theywould have considerably smaller target sample sizes and,
in contrast toRCTs involving patients, use financial incentives,
thus leading to different discontinuation patterns.3
Data Extraction and Follow-up of RCT Protocols
We used a web-based database for data extraction and man-
agement (http://www.squiekero.org/). Reviewers trained in
trial methodology signed confidentiality agreements, com-
pleted a calibration process, and then extracted relevant data
fromRCT protocols.3 The initial 310 protocols (30%) were ex-
tracted independently and in duplicate, and disagreements
were resolvedbydiscussion; the remainingprotocolswere ex-
tractedby a single investigator,withperiodic duplicate agree-
ment checks. We followed up on the completion status and
publication history of RCTs as of April 27, 2013, by using in-
formation from REC files and by conducting comprehensive
searches for corresponding publications in electronic data-
bases (MEDLINE, Embase, Cochrane CENTRAL register,
CINAHL, AMED, Google Scholar, and topic-specific data-
bases) and trial registers (ClinicalTrials.gov, WHO Interna-
tional Clinical Trials Registry Platform); details have been
reported.3Two investigatorsworking independentlyand indu-
plicate determined whether identified publications matched
the corresponding protocol.
If trial completion or publication status remained unclear,
the REC in charge contacted the investigators, sending them a
standardized questionnaire (eAppendix in Supplement).
Statistical Analysis
Trial completion and reported reasons for discontinuation are
presented as frequencies and percentageswith 95%CIs, strati-
fied by RCT sponsorship (industry vs investigator) and type of
participants(patientsvshealthyvolunteers).Weinvestigatedfac-
tors associated with RCT discontinuation due to poor recruit-
mentusingcomplete-casemultivariablehierarchical logistic re-
gressionwith protocol-level variables as fixed effects and the 6
RECsas randomintercept.Assumingdifferent recruitmentand
discontinuationpatterns,weexcludedfromthisregressionanaly-
sisRCTsdiscontinued for reasonsother thanpoor recruitment,
RCTs involving healthy volunteers only, cluster randomized
trials, and pilot RCTs.We examined the following prespecified
protocolvariables inourmodel: typeofcontrol intervention(pla-
ceboornotreatmentvsactive intervention),centerstatus(single
vsmulticenter), anyreportedrecruitmentprojection(yesvsno),
reportedmethodological or logistical support by a contract re-
search organization or clinical trial unit (yes vs no), trial spon-
sor (industry vs investigator), trial design (parallel vs crossover
or factorial), and planned sample size (increments of 100).3
Post hoc, we investigated trial discontinuation and type
of participants (patients vs healthy volunteers) as risk factors
for nonpublication of RCTs in a journal using complete-case
multivariable hierarchical logistic regression considering fac-
tors associated with nonpublication such as industry spon-
sorship, larger planned sample size, and single-center status
as additional covariables in the model, as previously
suggested.8 We calculated unadjusted and adjusted odds ra-
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tios with 95% CIs. We used the bootstrap procedure with 100
replications to investigate the stability of the estimated stan-
dard errors and 95% CIs. In prespecified sensitivity analyses
weusedanalternate thresholdof80%of the target sample size
achieved to define RCT discontinuation and used multiple-
imputation techniques to imputemissing covariable data.9 In
a post hoc sensitivity analysis we explored differences in dis-
continuation rates across countries.
DataanalyseswereconductedusingRversion3.0.1 (RProj-
ect for Statistical Computing; http://www.r-project.org/), and
Stata version 13.1 (StataCorp).P < .05 (2-sided)was set as level
of significance.
Results
RCT Protocols
Between2000and2003 the collaboratingRECs reviewed3819
study protocols (eFigure in Supplement). Of the 1080 poten-
tially eligibleRCTprotocols, 53werenever startedand 10RCTs
were ongoing (as of April 27, 2013), thus leaving 1017 RCTpro-
tocols for inclusion (894 protocols involving patients and 123
involving healthy volunteers).
MostpatientRCTshad industrysponsorshipandweremul-
ticenter,parallel-group, superiority trials inoncologyor thecar-
diovascular field, with a median planned sample size of 260
patients (interquartile range, 100-606) (Table 1, eTable 2 in
Supplement).RCTs involvinghealthyvolunteershadpredomi-
nantly industry sponsorship, usedmostly a crossover design,
and had amedian planned sample size of 20 participants (in-
terquartile range, 12-34).
Prevalence of Discontinued RCTs and Reporting to RECs
Overall, 253 of 1017 RCTs (24.9% [95% CI, 22.3%-27.6%]) were
discontinued, most frequently because of poor recruitment
(101/1017; 9.9% [95% CI, 8.2%-12.0%]). Other reasons for dis-
continuation are reported in Table 2. Discontinuation infor-
mationwas gathered fromREC files alone in 69 trials (27.3%),
publications alone in 85 (33.6%), investigator survey alone in
72 (28.5%), and from combined sources in 27 (10.7%).
Table 1. Characteristics of All Included Randomized Clinical Trials (RCTs)
Characteristic
No. (%)
RCTs Involving Patients
(n = 894)
RCTs Involving Healthy Volunteers
(n = 123)
All
(n = 1017)
Industry Sponsorship
(n = 551)
Investigator Sponsorship
(n = 343)
Industry Sponsorship
(n = 86)
Investigator Sponsorship
(n = 37)
Planned target sample size,
median (IQR)
350 (150-700) 150 (62-450) 20 (12-36) 16 (9-24) 220 (70-588)a
Planned centers
Multiple 520 (94.4) 221 (64.4) 6 (7.0) 3 (8.1) 750 (73.7)
Single 29 (5.3) 120 (35.0) 79 (91.9) 33 (89.2) 261 (25.7)
Unclear 2 (0.4) 2 (0.6) 1 (1.2) 1 (2.7) 6 (0.6)
Unit of randomization
Individuals 546 (99.1) 333 (97.1) 80 (93.0) 32 (86.5) 991 (97.4)
Clusters 3 (0.5) 9 (2.6) 0 (0.0) 1 (2.7) 13 (1.3)
Body parts 2 (0.4) 1 (0.3) 6 (7.0) 4 (10.8) 13 (1.3)
Study design
Parallel 526 (95.5) 310 (90.4) 33 (38.4) 14 (37.8) 883 (86.8)
Crossover 20 (3.6) 21 (6.1) 46 (53.5) 19 (51.4) 106 (10.4)
Factorial 4 (0.7) 11 (3.2) 3 (3.5) 0 (0.0) 18 (1.8)
Unclear 1 (0.2) 1 (0.3) 4 (4.7) 4 (10.8) 10 (1.0)
Study purpose
Superiority 398 (72.2) 254 (74.1) 30 (34.9) 16 (43.2) 698 (68.6)
Noninferiority 110 (20.0) 29 (8.5) 19 (22.1) 3 (8.1) 161 (15.8)
Unclear 43 (7.8) 60 (17.5) 37 (43.0) 18 (48.6) 158 (15.5)
Research ethics committee
Basel 156 (28.3) 65 (19.0) 55 (64.0) 3 (8.1) 279 (27.4)
Hamilton 101 (18.3) 77 (22.4) 4 (4.7) 3 (8.1) 185 (18.2)
Freiburg 165 (29.9) 107 (31.2) 8 (9.3) 16 (43.2) 296 (29.1)
Lausanne 89 (16.2) 60 (17.5) 15 (17.4) 12 (32.4) 176 (17.3)
Zurich 19 (3.4) 24 (7.0) 1 (1.2) 1 (2.7) 45 (4.4)
Lucerne 21 (3.8) 10 (2.9) 3 (3.5) 2 (5.4) 36 (3.5)
Labeled as pilot trial
Yes 32 (5.8) 37 (10.8) 7 (8.1) 7 (18.9) 83 (8.2)
No 519 (94.2) 306 (89.2) 79 (91.9) 30 (81.1) 934 (1.8)
Abbreviation: IQR, interquartile range.
a Missing data for planned target sample size in 18 trial protocols.
Epidemiology of Discontinued Randomized Trials Original Investigation Research
jama.com JAMA March 12, 2014 Volume 311, Number 10 1047
Downloaded From:  by a UNIVERSITE DE LAUSANNE User  on 10/13/2017
Copyright 2014 American Medical Association. All rights reserved.
AssessmentofRECfilesandidentifiedpublicationsshowed
that information about completion or publication status was
missing for 299RCTs. TheRECs sent surveyquestionnaires to
the investigators, of whom 240 responded (response rate,
80.3%). In total, 96 of 253 trial discontinuations (37.9% [95%
CI, 32.0%-44.3%]) were reported to RECs. The REC files in-
cludedthe informationabout trialdiscontinuationforRCTsdis-
continued for poor recruitment in 24 of 101 RCTs (23.8% [95%
CI, 16.1%-33.5%]); RCTs discontinued for administrative rea-
sons (such as strategic decisions from companies, conse-
quence of new recruitments from regulatory bodies, and
changeofworkplaceofprinciple investigators) in 15of 39RCTs
(38.5% [95%CI, 23.8%-55.3%]); RCTs discontinued for futility
in 16 of 37 RCTs (43.2% [95%CI, 27.5%-60.4%]); andRCTs dis-
continued for harm in 13 of 24 RCTs (54.2% [95% CI, 33.2%-
73.8%]).
Among the894RCTs involvingpatients, 249werediscon-
tinued (27.9% [95% CI, 25.0%-30.9%]), most frequently be-
cause of poor recruitment (100/894; 11.2% [95% CI, 9.2%-
13.5%]). In contrast, of the 123 RCTs involving healthy
volunteers, 4 were discontinued (3.3% [95% CI, 1.2%-8.6%]),
3 for administrative reasons and 1 for poor recruitment.
Discontinuation Due to Poor Recruitment
Trials discontinued because of poor recruitment achieved a
median percentage of target sample size of 40.9% (interquar-
tile range, 28.5%-59.8%). Only 3 RCTs recruited more than
80% of the target. Table 3 reports trial characteristics of
RCTs discontinued because of poor recruitment and charac-
teristics of completed RCTs. In multivariable analysis, indus-
try sponsorship (8.4% vs 26.5% for investigator sponsorship;
adjusted odds ratio, 0.25 [95% CI, 0.15-0.43]), and every
increment of 100 patients in the planned sample size (−0.7%;
adjusted odds ratio, 0.96 [95% CI, 0.92-1.00]) were associ-
ated with less frequent RCT discontinuation. Lack of docu-
mentation of any recruitment rate projection (based on ret-
rospective or prospective screening for eligible patients) in
the protocol was not associated with discontinuation due to
poor recruitment. All 9 RCT protocols that reported perform-
ing a full pilot study (ie, including informed consent of
patients) were, however, completed.
All sensitivity analyses left our results unchanged (eTable
3 in Supplement).We found no evidence for different discon-
tinuation rates across the 3 countries involved (likelihood ra-
tio test, P = .63).
Table 2. Prevalence of Randomized Clinical Trial (RCT) Discontinuation and Reported Reasons for Discontinuation
No. (%) [95% CI]
RCTs Involving Patients RCTs Involving Healthy Volunteers All
Sponsorship
All
(n = 894)
Full Journal
Publication
(n = 530)
Sponsorship
All
(n = 123)
Full Journal
Publication
(n = 37)
All
(n = 1017)
Full Journal
Publication
(n = 567)
Industry
(n = 551)
Investigator
(n = 343)
Industry
(n = 86)
Investigator
(n = 37)
Completion
status
Completed 394 (71.5)
[68.1-75.2]
181 (52.8)
[47.3-58.1]
575 (64.3)
[61.1-67.4]
417 (78.7)
[75.0-82.0]
81 (94.2)
[86.3-97.8]
28 (75.7)
[58.4-87.6]
109 (89.0)
[81.3-93.4]
37 (100.0)
[88-100]
684 (67.3)
[64.3-70.1]
454 (80.1)
[76.6-83.2]
Discontinued 119 (21.6)
[18.3-25.3]
130 (37.9)
[32.8-43.3]
249 (27.9)
[25.0-30.9]
113 (21.3)
[18.1-25.0]
1 (1.2)
[0.0-7.2]
3 (8.1)
[2.1-23.0]
4 (3.3)
[1.0-8.6]
0
[0.0-11.7]
253 (24.9)
[22.3-27.6]
113 (20.0)
[16.9-23.4]
Unclear 38 (6.9)
[5.0-9.4]
32 (9.3)
[6.6-13.0]
70 (7.8)
[6.2-9.8]
0
[0.0-0.9]
4 (4.7)
[1.5-12.1]
6 (16.2)
[6.8-32.7]
10 (8.1)
[4.2-14.8]
0
[0.0-11.7]
80 (7.7)
[6.3-9.71]
0
[0.0-0.8]
Reason for
discontinuation
Poor
recruitmenta
40 (7.3)
[5.3-9.8]
60 (17.5)
[13.7-22.0]
100 (11.2)
[9.2-13.5]
40 (7.5)
[5.5-10.2]
0
[0.0-5.3]
1 (2.7)
[0.1-15.8]
1 (0.8)
[0.04-5.1]
0
[0.0-11.7]
101 (9.9)
[8.2-12.0]
40 (7.1)
[5.1-9.6]
Futilityb 25 (4.5)
[3.0-6.7]
12 (3.5)
[1.9-6.2]
37 (4.1)
[3.0-5.7]
18 (3.4)
[2.1-5.4]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
37 (3.6)
[2.6-5.0]
18 (3.2)
[1.9-5.1]
Administrative
reasonsc
20 (3.6)
[2.3-5.7]
16 (4.7)
[2.8-7.6]
36 (4.0)
[2.9-5.6]
8 (1.5)
[0.7-3.1]
1 (1.2)
[0.0-7.2]
2 (5.4)
[0.9-19.5]
3 (2.4)
[0.6-7.5]
0
[0.0-11.7]
39 (3.8)
[2.8-5.3]
8 (1.4)
[0.7-2.9]
Harm 17 (3.1)
[1.9-5.0]
7 (2.0)
[0.9-4.3]
24 (2.7)
[1.8-4.0]
12 (2.3)
[1.2-4.0]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
24 (2.4)
[1.6-3.5]
12 (2.1)
[1.2-3.8]
Unknown
reasond
6 (1.1)
[0.4-2.5]
18 (5.3)
[3.2-8.3]
24 (2.7)
[1.8-4.0]
21 (4.0)
[2.6-6.0]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
24 (2.4)
[1.6-3.5]
21 (3.7)
[2.4-5.6]
Benefit 2 (0.4)
[0.06-1.5]
7 (2.0)
[0.9-4.2]
9 (1.0)
[0.5-2.0]
9 (1.7)
[0.8-3.3]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
9 (0.9)
[0.4-1.7]
9 (1.6)
[0.8-3.1]
External
evidence
6 (1.1)
[0.4-2.5]
2 (0.6)
[0.1-2.3]
8 (0.9)
[0.4-1.8]
2 (0.4)
[0.0-1.5]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
8 (0.8)
[0.4-1.6]
2 (0.4)
[0.1-1.4]
Lack of funding 1 (0.2)
[0.01-1.2]
4 (1.2)
[0.4-3.2]
5 (0.6)
[0.2-1.4]
0
[0.0-0.9]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
5 (0.5)
[0.2-1.2]
0
[0.0-0.8]
Other 2 (0.4)
[0.06-1.5]
4 (1.2)
[0.4-3.2]
6 (0.7)
[0.3-1.5]
3 (0.6)
[0.2-1.7]
0
[0.0-5.3]
0
[0.0-11.7]
0
[0.0-3.8]
0
[0.0-11.7]
6 (0.6)
[0.2-1.3]
3 (0.5)
[0.2-1.6]
a Some trials had an additional reason for discontinuation: benefit (n = 1), futility
(n = 2), and other reasons (n = 3).
b Includes randomized trials with adaptive designs that have been stopped after
the 1st (n = 5) or 2nd stage (n = 1).
c Includes strategic decisions from companies, consequence of new
requirements from regulatory bodies, and change of workplace of principal
investigators.
d Reasons for not achieving 90% of target sample size remained unclear.
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Publication of RCTs
Of the1017RCTs,567 (55.8%, [95%CI, 52.6%-58.8%])werepub-
lished as full journal articles as of April 27, 2013. Publication
information was obtained from REC files in 31 of 586 studies
(5.5%), fromsearchingelectronicdatabases in495 (87.3%), and
from the investigator survey in 41 (7.2%). Results from all 9
RCTsstoppedearly forbenefitwerepublished,but resultswere
published foronly40of 101 trialsdiscontinuedbecauseofpoor
recruitment (39.6% [95% CI, 30.2%-49.9%]) (Table 2). Multi-
variable analysis suggested thatdiscontinuedRCTsweremore
likely to remainunpublished,asweresingle-centerRCTs, those
with industry sponsorship, those involving healthy volun-
teers, and those with smaller sample sizes (Table 4).
Discussion
Our study found that 25% of initiated RCTs were discontin-
ued. Althoughdiscontinuationwas common for RCTs involv-
ing patients (28%), it was rare for RCTs involving healthy vol-
unteers (3%). The most commonly reported reason for RCT
discontinuationwaspoor recruitment (10%of includedRCTs).
We found that trials with investigator sponsorship (vs indus-
try sponsorship) and thosewith smaller planned sample sizes
were at higher risk of discontinuation due to poor recruit-
ment. Of discontinued RCTs, up to 60% remained unpub-
lished.Trial investigators rarely informedRECsabout trial dis-
continuation and publication.
A strength of our study was the full access to the files of
all trials approved by the collaborating RECs during
the study period. We systematically searched all documents
to capture any relevant information about the course of the
RCT such as issues of recruitment, changes in design, or
modification of target sample size. We published our own
study protocol,3 involved only trained methodologists in
data abstraction, and, to minimize chance associations,
considered only a limited number of variables in the statisti-
cal models. Our results proved robust in sensitivity
Table 4. Factors AssociatedWith Nonpublication of Randomized Clinical Trials (RCTs)a
Characteristics
RCTs, No. (%) Univariable Multivariable
Not Published
(n=451)
Published
(n=566) OR (95% CI)
P
Value OR (95% CI)
P
Value
Planned target sample size, median (IQR) 120 (40-330)b 303 (100-745)b 0.92 (0.89-0.94)c <.001 0.95 (0.92-0.97)c <.001
Multicenter status (vs single center) 280 (62.4) 470 (83.0) 0.33 (0.25-0.44) <.001 0.50 (0.32-0.76) .001
Industry sponsor (vs investigator) 279 (61.9) 358 (63.3) 0.94 (0.73-1.22) .65 1.68 (1.20-2.34) .002
Discontinued RCT (vs completed RCT) 140 (37.6)d 114 (20.1)d 2.41 (1.80-3.24) <.001 3.19 (2.29-4.43) <.001
RCT with patients (vs healthy volunteers) 364 (80.7) 530 (93.6) 0.27 (0.17-0.41) <.001 0.36 (0.20-0.63) <.001
Abbreviation: IQR, interquartile range.
a Complete-case multilevel logistic regression analysis of RCTs involving
patients and RCTs with healthy volunteers (research ethics committees as
random intercept); we excluded 12 RCTs with missing values for planned
target sample size (footnote “b”) and 81 RCTs with unclear completion status
(footnote “d”), for a total of 924 RCTs. A sensitivity analysis including these 93
RCTs (total n = 1017) with imputations for unclear completion status and
target sample sizes imputed throughmultiple imputation showed similar
results (eTable 3 in Supplement).
b Trials with missing values for sample size were excluded.
c In increments of 100.
d Trials with unclear completion status were excluded.
Table 3. Factors AssociatedWith Discontinuation of Randomized Clinical Trials (RCTs) Due to Poor Recruitment in RCTs Involving Patientsa
Characteristics
RCTs, No. (%) Univariable Multivariable
Discontinued Because of
Poor Recruitment
(n = 90)
Completed
(n = 526) OR (95% CI)
P
Value OR (95% CI)
P
Value
Planned target sample size, median (IQR) 180 (80-320)b 368 (154-800)b 0.95 (0.91-0.99)b,c .01 0.96 (0.92-1.00)b,c .04
Placebo/no active control (vs active-control
intervention)
53 (58.9) 321 (61.1) 0.89 (0.56-1.41 .63 0.81 (0.50-1.31) .39
Single-center status (vs multicenter) 19 (21.1) 53 (10.1) 2.41 (1.35-4.32) .003 0.66 (0.32-1.38) .27
Crossover design (vs parallel) 8 (8.9) 21 (4.0) 2.37 (1.01-5.53) .046 2.00 (0.75-5.33) .16
Reported methodological/logistical support
(vs not reported)
27 (30.0) 245 (46.7) 0.50 (0.31-0.81) .005 0.62 (0.37-1.06) .08
Reported recruitment projection
(vs not reported)
12 (13.3) 40 (7.6) 1.71 (0.84-3.47) .14 1.04 (0.50-2.22) .90
Industry sponsor (vs investigator) 34 (37.8) 371 (70.5) 0.25 (0.16-0.40) <.001 0.25 (0.15-0.43) <.001
Abbreviation: IQR, interquartile range.
a Complete-case multilevel logistic regression analysis of patient RCTs (research
ethics committees as random intercept); RCTs involving healthy volunteers
(n = 123), RCTs discontinued for reasons other than poor recruitment
(n = 149), RCTs with unclear completion status (n = 70), pilot RCTs (n = 51),
and cluster RCTs (n = 8) were excluded, for a total of 616 trials. In addition,
we excluded 5 RCTs with missing values for target sample size (footnote “b”).
A sensitivity analysis with target sample size imputed throughmultiple
imputation including these 5 RCTs showed similar results (eTable 3 in
Supplement).
b Trials with missing values for target sample size were excluded.
c In increments of 100.
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analyses applying alternate assumptions and statistical
approaches.
A limitation of our study was the low quality of the
included RCT protocols, in particular those for RCTs with
investigator sponsorship. Elements of trial methodology
potentially associated with trial discontinuation due to poor
recruitment, eg, recruitment projections, financial or nonfi-
nancial incentives, and study piloting, were frequently not
reported and thus limited our risk factor analysis. In our
regression analysis, we could not include some well-
established factors associated with nonpublication of RCTs,
such as results that are statistically nonsignificant or that
did not confirm study hypotheses, because we did not ask
investigators of unpublished RCTs for study results.10 We
used single data extraction for almost 70% of protocols,
thereby potentially increasing extraction errors. However,
we used prepiloted extraction forms with detailed written
instructions, conducted formal calibration exercises with all
data extractors, and checked extractions from a random
sample of protocols at several points during the process.
Agreement was good, with no more than 2 discrepancies in
30 extracted answers. All outcome data on discontinuation
and publication of RCTs were verified by a second investiga-
tor. Last, we used a convenience sample of 6 RECs in 3
countries. We cannot say whether they are representative
for other RECs in these or other countries; to our knowl-
edge, they are not in any way particular.
The overall RCT discontinuation rate of 25% (253/1017)
in our study is identical to estimates reported from Spain
(31/123 [25%])11 and Australia (50/197 [25%]).12 Other studies
reported lower rates of discontinuation from the United
Kingdom (25/195 [13%]),13 France (34/269 [13%]),14 and Swit-
zerland (57/508 [11%])8 or higher rates from the Netherlands
(45/135 [33%])6 and the United States (37/82 [45%]).5 Likely
explanations for these differences are (1) the method used
to determine trial discontinuation (eg, surveys with 30% or
more nonresponders potentially underestimate RCT
discontinuation),13,14 (2) different proportions of industry-
sponsored RCTs, (3) selected types of RCTs (eg, those focus-
ing only on drug trials),8 and (4) chance.
Various studies suggest that poor recruitment is common
and a major problem for clinical trials.2,13,15-17 Although poor
recruitment was the predominantly reported reason for trial
discontinuation inour study, theoverall frequencyof 10%was
relatively low.3 The problem appears, however, more severe
with investigator-sponsoredRCTs involvingpatients.Ananaly-
sis of 122multicenter RCTs funded by 2 public UK health care
sponsors found that trial discontinuation due to poor recruit-
ment occurred in up to 20% of trials,4 which is similar to our
estimate for patient RCTs with investigator sponsorship. The
above-mentionedDutch study found that recruitmentwas in-
sufficient in 40%ofRCTswith investigator sponsorship.6Our
findings suggest that sufficient fundingandprofessional plan-
ning and conduct of RCTs (ie, common features of RCTs with
industry sponsorship) are associatedwithmore successful re-
cruitment.LargerRCTsmightbebetterorganized fromtheout-
set (eg, within established research networks including mul-
tiple centers andexperienced investigators) andbetter able to
respond to recruitment challenges.
Overall, 56% of RCTs were published as full journal ar-
ticles. This publication rate is higher than reported for most
previous study cohorts.10 Reasons likely include our strict fo-
cus on RCTs and the longer follow-up period of 9 to 13 years
after protocol approval for trials to get published. ThoseRCTs
discontinued for early apparent benefit are frequently pub-
lished in highly ranked, peer-reviewed journals18; all 9 RCTs
fromthepresent study thatwerestoppedearly forbenefitwere
published as full journal articles. Our analysis suggests, how-
ever, that RCT discontinuation for other reasons is one of the
major factors driving nonpublication of RCTs.
For investigator-sponsored RCTs, stakeholders including
trial investigators, funding agencies, and RECs need to de-
velop strategies to prevent trial discontinuation due to poor
recruitment. Based on our data and a previous study,19 retro-
spective or prospective screening of patients appears to hold
little promise in estimating recruitment rates, but conduct-
ing a full pilot study including consent procedures might be
effective. Further research is necessary to determine the op-
timal length of pilot studies and to develop reliable predic-
tion models for recruitment performance.20 Recruitment
should be closely monitored and contingency plans in place
if it is lower than expected. Strategies to improve recruitment
havebeen tested21,22 andcouldpossiblybecombined,depend-
ing on the setting and area of investigation. The nonpublica-
tion of results from discontinued—or from completed—RCTs
represents a waste of valid data that could contribute to sys-
tematic reviews andmeta-analyses.
Conclusions
In this sample of trials based on RCT protocols from 6 RECs,
discontinuationwascommon,withpoor recruitmentbeing the
most frequently reported reason. Greater efforts are needed
tomake certain that trial discontinuation is reported to RECs
and that results of discontinued trials are published.
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